34results about How to "Simple extraction and separation process" patented technology

The invention discloses novel plant small-molecule peptides, particularly relates to small-molecule peptides of a sunflower head as well as a preparation method and medical application of the small-molecule peptides, and further discloses medical application of the small-molecule peptides of the sunflower head to treatment of gout diseases. The small-molecule peptides of the sunflower head are low in molecular weight of proteins and can be directly absorbed by a human body without the digestion system; the peptides can be absorbed quickly and takes effect efficiently; a related extracting and separating process is simple and is easy to operate; no special equipment is required, and the cost is low; reagents used are pollution-free to the environment. The small-molecule peptides are suitable for large-scale industrial production.

The invention discloses applications of an eucommia ulmoide total alkaloid for preparing a combination with a sedative-hypnotic effect, and also discloses applications of the eucommia ulmoide total alkaloid for preparing the combination used for treatment of insomnia, anxiety or convulsion; the eucommia ulmoide total alkaloid is prepared by extracting, separating and purifying an eucommia ulmoidespark, an eucommia ulmoide leaf, an eucommia ulmoide male flower and / or eucommia ulmoide whole-plant. The invention extracts, separates and purifies the plant eucommia ulmoide. The invention obtains the eucommia ulmoide total alkaloid by extracting, separating and purifying plant eucommia ulmoide and carries out the application research of the eucommia ulmoide total alkaloid in the sedative-hypnotic field; the result indicates that the eucommia ulmoide total alkaloid has obvious sedative-hypnotic effect and anti-convulsion effect, is a natural active matter for researching and developing a novel health-caring food and new drugs with the sedative-hypnotic effect, can be used for curing the nervous system diseases such as insomnia, anxiety or convulsion and has no side effects or spiritual dependency.

The invention belongs to the technical field of extraction of Chinese herbal medicine, and particularly relates to a herba centellae extract with anti-inflammation and anti-sensitivity effects. The herba centellae extract is prepared by adopting the following preparation method: S1. adding ethanol into herba centellae powder for extraction, carrying out ultrasonic assisted extraction, then centrifuging or filtering, and collecting a filtrate; S2. adding activated carbon to the filtrate obtained in step 1 for decoloring, centrifuging, and collecting a decolored filtrate; S3. concentrating the decolored filtrated obtained in step 2, adding a chitosan liquid for decontamination, filtering, and collecting a decontaminated filtrate; S4. adding macroporous adsorption resin to the decontaminated filtrate for purification, and eluting with ethanol to obtain an eluent; S5. concentrating, desalting and drying the eluent obtained in step 4 to obtain the herba centellae extract, wherein in S1, the concentration of ethanol is 60-90%, the ultrasonic power is 228W-380W, and the material-to-liquid ratio is 1:20-80. The herba centellae extract provided by the invention has remarkable anti-inflammation and anti-sensitivity effects, is prominent in oxidation resistant and free radical removal effects, and can be widely applied to skin care products with anti-inflammation and anti-sensitivity effects.

The invention relates to a method for preparing Fructus Aurantii ingredients having anti-liquid-accumulation activity and a use, concretely to a Fructus Aurantii extractive containing 20 to 42 % of naringin and 20 to 48 % of neohesperidin. The Fructus Aurantii extractive is prepared by the following method comprising smashing the Fructus Aurantii medicinal materials, adding 20 to 90 % ethanol, extracting for 1 to 3 times under reflux by heating, combining filtrates to get extracting solutions, condensing the extracting solutions to get extractum, mixing the extractum with macroporous resin, purifying with a macroporous resin column, collecting 60 to 80 % ethanol eluates, condensing, purifying with a polyamide column, collecting 20 % ethanol eluates, condensing and drying to get the Fructus Aurantii ingredients. The Fructus Aurantii extractive can be used for preparing medicaments for treating non-alcoholic fatty liver.

The invention relates to an alkaloid compound extracted and prepared from a cat bean and a valid target, wherein, the cat bean is used as a raw material, the valid target is obtained through crushing, solvent extraction, separation and purification by resin or silica gel column chromatography and other methods, and the compound, 1, 2-dihydro-3-guanido-6-hydroxymethyl-1-methylpyrazine-2-ketone, namely cat-bean guanidine, is obtained by separation of the valid target. Pharmacodynamical experiments prove that: the compound has sedative-hypnotic function, and can be used as a pharmaceutical and chemical raw material and be prepared into sedative-hypnotic preparation.

The invention relates to an application of a phyllanthus urinaria polysaccharide component in preparing a drug for resisting a hepatitis B virus, and belongs to the field of medicine. The phyllanthus urinaria polysaccharide component is a phyllanthus urinaria polysaccharide component PUIP II which comprises rhamnose, arabinose, mannose and glucose at a molar ratio of 0.11:0.36:0.08:0.45. The phyllanthus urinaria polysaccharide component is artificially extracted, separated and purified by a medicinal plant, namely phyllanthus urinaria. An in-vitro bioactivity experiment indicates that the phyllanthus urinaria polysaccharide component PUIP II can inhibit secretion of HBsAg and HBeAg and reproduction of HBV-DNA (hepatitis B virus-deoxyribose nucleic acid) in HepG2.2.2.15 cell culture, and has a certain in-vitro HBV activity resistance effect, and an in-vivo activity experiment indicates that the PUIP II has an obvious inhibiting effect on DHBVDNA (duck hepatitis B virus deoxyribose nucleic acid) in a duck, is smaller in bounce, and can be used for preparing the drug for resisting the hepatitis B virus and for preparing health care products for protecting a liver.

The preparation of 1,2-diacyl-3-(6-deoxy-6-sulfo- alpha-D-glucopyranosyl)-sn-glycerin ester includes the steps of leaching crushed sea algae with organic solvent, adding water solution of potassium chloride into filtrate to delaminate and depression evaporating organic phase to obtain general algae ester, mounting diethyl amino ethyl cellulose through serial treatment in column; dissolving general algae ester in mixed solvent of chloroform and methanol, depurating in the column with the mixed chloroform and methanol solvent and eluted with mixed solvent of CHCl3, CH3OH and NH3.H2O to obtain coarse product; and purifying with mixed of CHCl3, CH3OH and KCl solution and evaporation to eliminate organic phase; and dissolving the product in methanol, eluting with acetone in activated silica gel column and evaporating to obtain purified product.

The invention relates to use of ligustilide in preparing anti-thrombotic medicines, in particular to a rhizoma ligustici wallichii extract. The rhizoma ligustici wallichii extract contains 30-90 percent of ligustilide. The extract is prepared by adopting a method comprising the following steps of: crushing a rhizoma ligustici wallichii medicinal material; then, soaking by using 70-99 percent of alcohol (for example 75-98 percent), and performing reflux extraction for 1-4 times; merging extracting solutions; concentrating; extracting by using petroleum ether; recovering solvents from the merged extracting solutions until dry to obtain petroleum ether extracting extractum; adding part of petroleum ether extracting extractum to positive-phase silica gel and mixing to exceed a positive-phase silica gel column; performing elution by taking the petroleum ether and an ethyl acetate solution as eluents; collecting the eluents; concentrating to obtain the rhizoma ligustici wallichii extract, wherein the volume ratio of the petroleum ether to the ethyl acetate solution is 50:(0.5-5) [for example 50:(0.5-3)].

The invention discloses an application of a Phyllanthus urinaria polysaccharide PUIP III in the preparation of anti-hepatitis B virus medicines. The Phyllanthus urinaria polysaccharide PUIP III is composed of rhamnose, arabinose, mannose and glucose, the molar ratio of rhamnose to arabinose to mannose to glucose is 0.27:0.28:0.1:0.35, and the molecular weight of the Phyllanthus urinaria polysaccharide is 418793.5. The Phyllanthus urinaria polysaccharide is obtained through artificially extracting the medicinal plant Phyllanthus urinaria, separating and purifying. In-vitro biological activity experiments show that the PUIP III can inhibit the HBsAg and HBeAg secretion and the HBV-DNA duplication in the HepG2.2.2.15 cell culture, and has a certain in-vitro anti-HBV activity; and in-vivo activity experiments show that the PUIP III has an obvious inhibition effect on DHBVDNA in ducks, has small rebound, and can be used for preparing the anti-hepatitis B virus medicines and liver protection healthcare products.

The invention discloses application of eucommia ulmoides extracts in the preparation of compositions for tranquilizing and inducing sleep and application of the eucommia ulmoides extracts in the preparation of compositions for treating insomnia, anxiety neurosis or convulsion. The eucommia ulmoides extracts are continuously extracted from eucommia bark, eucommia leaves, eucommia male flowers and\or eucommia whole plants by petroleum ether, ethyl acetate, normal butanol, ethanol and water. The eucommia ulmoides extracts are obtained by extracting from eucommia plants. And results of researcheson the application of the eucommia ulmoides extracts in the field of tranquilization and sleep induction show that the eucommia ulmoides extracts have remarkable effects of tranquilizing and inducingsleep and resisting convulsion, wherein the ethyl acetate extract of eucommia and the normal butanol extract of the eucommia have more obvious effects. The eucommia ulmoides extracts are natural active materials for researching and developing novel health-care foods and new drugs for tranquilizing and inducing sleep, and can be applied to the treatment of nervous system diseases such as insomnia,anxiety neurosis and convulsion without side effects and psychic dependence.

The invention provides a method for extracting pinostrobin and beta-sitosterol from exocarp of kiskatom, which belongs to the technical field of pinostrobin and beta-sitosterol extracting methods. The method comprises the following steps: washing and crushing the expocarp of the kiskatom; and then diacolating and extracting the expocarp after the expocarp is swelled by ethanol, and concentrating the collected diacolation solution to prepare a concentrated solution; extracting the concentrated solution by an organic solvent to prepare extract dry powder; and separating the extract dry powder by silica gel column chromatography with the following steps: a) carrying out gradient elution on the extract dry powder by sherwood oil and a sherwood oil-ethyl acetate mixed solution with volume ratio of between 45:1 and 15:1 respectively, and combining two kinds of eluate; and b) carrying out the gradient elution on the combined eluate by the sherwood oil-ethyl acetate mixed solution with volumeratio of between 10:1 and 1:20, and concentrating and crystallizing the combined eluate in the reduced pressure to prepare pinostrobin coarse crystal and beta-sitosterol coarse crystal; and carrying out recrystallization treatment to prepare pinostrobin crystal and beta-sitosterol crystal. The method has the advantages of simple process and low manufacturing cost, and the contents of the preparedpinostrobin crystal and the beta-sitosterol crystal are more than 98 percent.

The invention provides a composition and its preparation method and application. The technical scheme uses madder root as raw material, extracts with ethyl acetate after ethanol reflux extraction, the extract is extracted with sodium carbonate solution, the extract is acidified and filtered to collect the filter residue, and then dissolved in chloroform-methanol with Sephadex LH 20 Separation to obtain madderin, isordizin, and hydroxyrubidin respectively. In the present invention, the rubikin, isorubidin and hydroxyrubidin are mixed in a weight ratio of 5:3:2 to obtain an antiallergic composition with exact ingredients. In vitro experiments show that the composition of the present invention can effectively inhibit the secretion of IgE from cells, thereby realizing the immune regulation effect; in vivo experiments prove that oral administration of the composition can exactly reduce the expression level of IgE, and then realize the anti-allergic effect, and the effect is comprehensively better than that of the natural extract of rubidin things and parties. The invention can be used to prepare food or medicine for treating food allergy, and compared with hormone medicine and antihistamine medicine, the invention has low toxicity and is safe and reliable.

A method for preparing hair tobacco essential oil, characterized in that: using combined technology of subcritical extraction and molecular distillation to extract and separate hair tobacco as a raw material, so as to effectively increase the content of volatile aroma substances in the essential oil. Applying tobacco essential oil to cigarettes can improve the aroma quality and taste of cigarettes, and improve the sensory comfort of cigarettes; applying tobacco essential oil to e-cigarette liquids can give e-cigarettes a strong aroma of tobacco and enhance the sense of satisfaction , reduce the sweetness of the solvent. The biggest features of the present invention are: (1) Compared with steam distillation, the extraction rate of essential oil is greatly improved; (2) The combination of subcritical extraction and molecular distillation technology reduces the content of non-volatile macromolecular substances in essential oil, The content of volatile aroma substances is increased, among which the content of nicotine, solanone, neophytadiene, macrostigmatrienone, farnesyl acetone, etc. is significantly increased compared with subcritical extracted absolute oil, making the characteristic aroma of tobacco more for highlighting.

The invention discloses applications of an eucommia ulmoide total alkaloid for preparing a combination with a sedative-hypnotic effect, and also discloses applications of the eucommia ulmoide total alkaloid for preparing the combination used for treatment of insomnia, anxiety or convulsion; the eucommia ulmoide total alkaloid is prepared by extracting, separating and purifying an eucommia ulmoidespark, an eucommia ulmoide leaf, an eucommia ulmoide male flower and / or eucommia ulmoide whole-plant. The invention extracts, separates and purifies the plant eucommia ulmoide. The invention obtains the eucommia ulmoide total alkaloid by extracting, separating and purifying plant eucommia ulmoide and carries out the application research of the eucommia ulmoide total alkaloid in the sedative-hypnotic field; the result indicates that the eucommia ulmoide total alkaloid has obvious sedative-hypnotic effect and anti-convulsion effect, is a natural active matter for researching and developing a novel health-caring food and new drugs with the sedative-hypnotic effect, can be used for curing the nervous system diseases such as insomnia, anxiety or convulsion and has no side effects or spiritual dependency.

The invention discloses a phenethyl alcohol glycoside compound extracted from a common cephalanoplos herb and application. The phenethyl alcohol glycoside compound is shown as a formula (I). According to the principle of 'homology of medicine and food', the common cephalanoplos herb is selected as a research object, and a modern extracting and separating technology is adopted to simply, conveniently and effectively separate and purify the common cephalanoplos herb so as to obtain the new phenethyl alcohol glycoside compound. The compound is novel in structure, has very good lipid-lowering activity and an anti-oxidation effect, can be applied to preparation of lipid-lowering medicines, especially to preparation of weight-reducing medicines, and can be also applied to preparation of anti-oxidation medicines, especially to preparation of free-radical scavenger medicines. An important theoretical basis is laid for further development of novel weight-reducing medicines remarkable in treating effect and small in toxic and side effect and medicines having the anti-oxidation effect.

The invention provides method for extracting walnut ketones from epicarps of carya cathayensis Sarg and preparing walnut ketone standard product. The method comprises the steps of: firstly, crushing the epicarps of the carya cathayensis Sargs, moistening with aqueous ammonia, adding 95 percent of ethanol solution, carrying out hot reflux extraction, extracting extract with chloroform to obtain carya cathayensis Sarg ketone sample liquid, concentrating the sample liquid, purifying by thin layer chromatography to obtain rough walnut ketone, further purifying the rough walnut ketone by using C18 reverse-phase column chromatography, collecting the rough walnut ketone eluent by segments, combining the eluent with purity larger than 95 percent detected by HPLC (High Performance Liquid Chromatography), and carrying out nitrogen blowing to remove a solvent, thus obtaining the walnut ketone standard product. For the method, the extraction process is simple, the walnut ketone has high yield and high purity, theoretical and practical application basis can be provided for comprehensively utilizing carya cathayensis Sarg resources by taking the epicarps of the carya cathayensis Sargs as raw materials, thus having an effect on changing wastes into treasures.

The invention discloses a method for extracting astaxanthin from haematococcus pluvialis by a double-aqueous-phase coupled wall breaking technology. A double-aqueous-phase separating system is coupled with a freeze-thawing wall breaking technology through experiments, and the processes of wall breaking, extracting and separating are coupled through the introduction of the double-aqueous-phase system. The astaxanthin can be effectively separated from algae residues and various impurity components by a simple liquid separating method during wall breaking and extracting, and the purity and the extracting rate of the astaxanthin are effectively improved. The extracting and separating processes are reduced, and meanwhile, a freeze-thawing agent and an extractant are consistent with the phase forming substances of the double-aqueous-phase system. The types and the dosage of reagents are reduced, and the used reagents are environment-friendly and easy to recycle.